The pharmaceutical industry is at a crossroads. Rising healthcare costs and patient frustration with traditional channels fuel the rise of direct-to-patient (DTP) drug sales models. While this approach promises increased access and transparency, it also raises concerns about its impact on the sacred doctor-patient relationship.